Skip to main content

The RheumNow Week in Review – 4 August 2017

Aug 04, 2017 3:00 am

Dr. Jack Cush reviews new FDA decisions on sirukumab and tofacitinib as well as other news items from the past week on 

  1. Amgen submitted its Biologic Licence application to the FDA for Denosumab in Rx of Glucorticoid induced Osteoporosis
  2. 165 scleroderma pts double pos for centromere & anti–IFI-16 Abs incr. risk for digital vascular events, >3 fold higher odds of Severe Raynauds  
  3. IBD clinic study shows CT-Dx sacroiliitis found in 15% of 233 Crohns, 16.9%, of 83 UC pts & 5.6% 108 controls
  4. Among 608 SSc pts 3% developed Scl renal crisis - risk w/ digital gangrene, pred >15, alb
  5. Hospitalizationsfor Serious infections increased from 90 to 206  per 100,000 PY from 1993-2013. Sepsis tripled. But pneumonia, UTI & OIs decreased
  6. No Increase in Malformations with Etanercept Use During Pregnancy
  7. Lupus Hospitalizations are Common 
  8. Arthritis Advisory Panel Votes Down Sirukumab  
  9. FDA Arthritis Advisory Panel Endorses Tofacitinib Approval for Psoriatic Arthritis 
The author has received compensation as an advisor or consultant on this subject

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.